Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.45 USD
+0.05 (2.08%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.40 -0.05 (-2.04%) 6:36 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Aytu BioPharma Inc. [AYTU]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Pediatric Portfolio Performing Strong and Consumer Health Margins Expected to Improve; Reit. Buy With PT Adjusted to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Record Fiscal 1Q23 Revenues Buoyed by Strong Rx Business Growth; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Record Fiscal 4Q22 Revenues Buoyed by Strong Rx Business Growth; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Record Fiscal 4Q22 Revenues Buoyed by Strong Rx Business Growth; Reiterate Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Initiation of Phase 3 PREVEnt Trial of AR101 in VEDS; Reiterate Buy With an Adjusted PT of $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
AR101 Fast Track and Orphan Drug Designation Granted for VEDS; Reiterate Buy With an Adjusted PT of $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Scientific Evidence Builds Support for Further Healight Advancement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Specialty Revenue and Pipeline Growth at an Increasingly Attractive Value; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Addition of Rare Disease Asset Positions Pediatric Portfolio for Accelerated Growth; Reiterate Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
We''re Positive on the Merger With Neos; Reiterate Buy With an Adjusted $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Fiscal 1Q21 Revenue Now at a New Level; Reiterate Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Full Integration of Rx and Consumer Health Business Segments Has Taken Form; Reiterate Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Healight Technology Represents a Novel Anti-COVID-19 Approach
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Adjusting for COVID-19 Impacts in Calendar 2Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
FDA Issues EUA for Aytu''s COVID-19 IgG/IgM Rapid Test; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Medical - Biomedical and Genetics
Putting Together the Right Parts for Organic Growth; Initiating Coverage at Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aytu BioPharma Inc.
Industry: Unclassified
We are terminating our coverage due to reallocation of resources within the research department
Provider: H.C. Wainwright & Co., Inc.
Company: Aytu BioPharma Inc.
Industry: Unclassified
We are hereby terminating our coverage due to reallocation of resources within the research department.
Provider: Rodman & Renshaw, Co.